Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Pulmonology news in December 2025 closed the year with landmark regulatory advances that expanded treatment options for historically underserved respiratory diseases. FDA approvals of nerandomilast for idiopathic pulmonary fibrosis—the first new idiopathic pulmonary fibrosis (IPF) therapy in more than a decade—and depemokimab-ulaa for severe eosinophilic asthma highlighted parallel progress toward disease modification and reduced treatment burden, supported by robust phase 3 data demonstrating meaningful clinical benefit with favorable safety profiles.

Alongside these approvals, late-year data and expert commentary reinforced a broader shift toward precision, trait-based respiratory care. New evidence showing pulmonary rehabilitation can reduce type 2 airway inflammation in select asthma populations complemented discussions on biomarker-driven management across asthma and chronic obstructive pulmonary disease (COPD), while persistent gaps in COPD and lung cancer screening underscored that translating innovation into improved outcomes will also require better implementation of existing, evidence-based tools.

Check out this December 2025 pulmonology month in review for a recap of HCPLive’s coverage of the top news and research from the past few weeks:

Nerandomilast Nets First New FDA Approval for Idiopathic Pulmonary Fibrosis in Over 10 Years

The FDA has approved nerandomilast 9 mg and 18 mg (Jascayd; Boehringer Ingelheim) for adults with idiopathic pulmonary fibrosis, marking the first new IPF therapy approved in more than a decade. The decision was supported by phase 3 FIBRONEER-IPF data showing significantly reduced decline in forced vital capacity versus placebo, with a generally well-tolerated safety profile.

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

The FDA has approved GSK’s depemokimab-ulaa (Exdensur) as an add-on maintenance therapy for severe eosinophilic asthma in patients aged 12 years and older, introducing the first ultra–long-acting biologic in this space with twice-yearly dosing. The approval was supported by data from the phase 3 SWIFT-1 and SWIFT-2 trials demonstrating significant reductions inannualized asthma exacerbations compared with placebo while maintaining a safety profile comparable to standard of care.

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary rehabilitation (PR) was shown to meaningfully reduce airway inflammation in people with asthma who began treatment with elevated FeNO, with the high-FeNO group experiencing a 40% drop in levels during the 3-week program. Improvements in asthma control and exercise capacity occurred across all baseline FeNO categories, but the anti-inflammatory effect was exclusive to those with high initial FeNO.
4. 

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

In this HCPLive expert discussion moderated by Joseph Khabbaza, MD, clinicians examine how the FDA approval of mepolizumab for eosinophilic COPD could mark a turning point in a field long limited to symptom-focused therapies. Drawing on phase 3 MATINEE data, the panel highlights its potential to reduce exacerbations, limit systemic steroid exposure, and usher COPD care toward a more asthma-like, biomarker-driven precision model.

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Despite well-established screening tools and expanded eligibility criteria, COPD and lung cancer remain profoundly underdiagnosed in the US, with most patients still identified at advanced stages when survival benefits are limited. Experts point to systemic access gaps, clinician hesitation, and persistent disease stigma as key barriers, underscoring that improving outcomes in 2026 will depend less on new technology than on using the tools already proven to work.

Articles

December 2025 marked significant regulatory advancements in pulmonology, with FDA approvals of nerandomilast for idiopathic pulmonary fibrosis and depemokimab-ulaa for severe eosinophilic asthma, both supported by robust phase 3 data. These approvals highlight a shift towards precision, trait-based respiratory care, emphasizing disease modification and reduced treatment burden. Pulmonary rehabilitation showed potential in reducing type 2 airway inflammation in asthma, while discussions on biomarker-driven management for asthma and COPD gained traction. However, challenges in COPD and lung cancer screening persist, necessitating better implementation of existing tools.

December 2025 saw new data on asthma therapies and new insights from experts on continuing trends in the field.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

5 Pulmonology Headlines You Missed in December 2025

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 has a substantial effect on patients with 

, with new research suggesting it may accelerate disease progression, particularly in the early stages.

Additionally, the findings highlight a disproportionate diagnosis of depression in patients with end-stage kidney disease, with investigators suggesting there may be an increased psychological burden as kidney function declines.

“From a clinical standpoint, implementing systematic depression screening could meaningfully change CKD care pathways,” wrote study investigator Abdullah Al-Mamun, PhD, an Assistant Professor in the Department of Pharmaceutical Systems and Policy from the West Virginia University School of Pharmacy, and colleagues.

The previous literature in CKD has linked the disease burden to increased depression instances, and, in turn, adverse health outcomes. A 

 paired CKD and social frailty, especially in patients in advanced stages undergoing hemodialysis, with an increased risk of depression. Meanwhile, another study found CKD patients with depressive symptoms were more likely to initiate dialysis or experience all-cause mortality, pointing to a potential link between mental health and disease trajectory. Another study observed an association of depressive symptoms with a 2.25-fold higher risk of progression to dialysis over 3 years.

In this retrospective cohort analysis, Al-Mamun and colleagues aimed to further evaluate the association between depression and CKD, especially beginning with early stages. They extracted data from the TriNetX electronic medical record database of patients with a CKD diagnosis. The primary objective included key independent variables such as diagnosis of depression or anxiety, identified by ICD codes. Secondary objectives were CKD stages ≥ 3, 4, and 5, as defined by Kidney Disease Improving Global Outcomes (KDIGO).

The primary outcome was progression to kidney disease, with an eGFR < 60 ml/min/bsa and > 40% decline in eGFR from the initial screening, while the secondary outcome was diagnosis of depression.

The study included adults ≥ 18 years of age with baseline CKD at > 1 year of follow-up data. The primary objective cohort was dichotomized into depression or no depression, and the secondary objective cohort was categorized by CKD stages.

In Kaplan-Meier curve analysis, investigators found faster kidney disease progression in patients with depression compared to patients without (

<.0001). In the adjusted Cox model, depression was significantly associated with an increased risk of kidney disease progression 1.94 (95% Confidence Interval [CI], 1.77–2.11, 

Among the 3 CKD stage groups, the survival probability decreased most rapidly for patients in stage 5, followed by stage 4, and then stage ≤3, with investigators positing it indicates patients in more advanced stages of CKD are more likely to develop depression earlier. Additionally, the differences between the survival curves for the CKD stages were statistically significant (

<.0001), suggesting a strong association between CKD stage and the time to depression onset.

Furthermore, investigators reported an increased risk of developing depression in patients in stage 4 compared to those in stage ≤3 (Hazard Ratio [HR], 1.26 [1.17–1.35]; 

< .05), and those in Stage 5 had an even higher increase in risk (HR, 1.38 [1.23–1.54]; 

“The findings of this study underscore a significant association between depression and CKD progression, particularly in the earlier stages,” concluded investigators. “Our results show that patients with a diagnosis of depression following their CKD diagnosis had a higher likelihood of kidney disease progression compared to those without depression.”

Jeun KJ, Brothers T, Khaled Shawwa, Al-Mamun MA. A retrospective cohort study on the bidirectional association between depression and chronic kidney disease. Frontiers in Nephrology. 2026;5. doi:

https://doi.org/10.3389/fneph.2025.1743594

Gabriela D, Luma Geraigire, Ferreira S, et al. Predictors of Social Frailty and Depression in Brazilian Patients With Chronic Kidney Disease: A Cross‐Sectional Study. 

Geriatrics and gerontology international/Geriatrics & gerontology international

Shen Y, Chen Y, Huang S, Yao X, Kanwar YS, Zhan M. The Association between Symptoms of Depression and Anxiety, Quality of Life, and Diabetic Kidney Disease among Chinese Adults: A Cross-Sectional Study. 

International Journal of Environmental Research and Public Health

Zhang Z, He P, Liu M, et al. Association of Depressive Symptoms with Rapid Kidney Function Decline in Adults with Normal Kidney Function. 

Clinical Journal of the American Society of Nephrology

Depression significantly impacts chronic kidney disease (CKD) patients, potentially accelerating disease progression, especially in early stages. Research indicates a higher prevalence of depression in end-stage kidney disease, suggesting increased psychological burden as kidney function declines. Systematic depression screening could alter CKD care pathways. Studies link CKD burden to increased depression and adverse health outcomes, with depressive symptoms associated with higher dialysis initiation and mortality risks. A retrospective cohort analysis found depression significantly associated with faster CKD progression, particularly in advanced stages, highlighting the need for integrated mental health management in CKD care.

A retrospective cohort analysis reports data on a two-sided relationship between depression diagnosis and chronic kidney disease progression. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Depression's Implied Bilateral Link With Chronic Kidney Disease Progression

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The American Gastroenterological Association (AGA) has released a clinical practice update on the evaluation and management of refractory constipation.

, on January 7, 2025, outlines 14 best-practice advice statements to help clinicians accurately diagnose and manage refractory constipation and to identify which patients may benefit from surgical intervention.

Constipation is a common disorder affecting approximately 1 out of every 6-7 people worldwide, and annually leading to > 1.5 million healthcare provider visits in the United States alone. While clinicians today have a wide therapeutic armamentarium, including osmotic and stimulant laxatives, secretagogues, and prokinetic agents, as well as emerging device-based therapeutic approach designed to enhance colonic motility without pharmacologic action like the vibrating capsule, some patients still do not respond to treatment.

“Though most patients with chronic constipation respond to standard treatments, a subset remains refractory to available therapies and merit the designation of ‘refractory.’ Such patients consume significant healthcare resources and frequently present to tertiary care centers,” Kyle Staller, MD, MPH, director of the Gastrointestinal Motility Laboratory at Mass General., and colleagues wrote.

Commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board, the review is designed to provide best practice advice on 14 key clinical issues related to the diagnosis, treatment, and medical and surgical management of patients with refractory constipation.

Acknowledging that refractory constipation is relatively rare, the document recommends clinicians systematically exclude correctable secondary causes such as medications, neurologic disorders, and defecatory disorders, confirm the presence of slow colonic transit, and ensure that patients have undergone adequate trials of over-the-counter and Food and Drug Administration–approved medications and nonpharmacologic therapies, including combinations thereof.

While the update says surgical treatments like colectomy can be considered in patients who fail available treatments, the authors note surgical treatment of chronic constipation is associated with increased risk of complications and a not insignificant number of unsatisfactory outcomes. Prior to advising surgery, it is recommended that clinicians confirm slow colonic transit, exclude concurrent defecatory disorders, and evaluate for severe, symptomatic delays in gastric emptying or small bowel dysmotility.

Because psychological comorbidities may exacerbate symptoms and adversely affect surgical outcomes, preoperative psychological evaluation is advised to assess suitability for surgery.

Relative contraindications to surgical treatment of refractory constipation include clinically significant upper-gut dysmotility, severe, untreated psychiatric disease, and predominant complaints of bloating and/or abdominal pain.

In uncertain cases, the authors note a temporary diverting loop ileostomy may help predict the potential response to colectomy, but that a colectomy with ileorectal anastomosis should only be offered to patients without ongoing defecatory disorders.

Of note, the authors caution that even with careful assessment as outlined in the practice update, the decision to pursue surgery for refractory constipation should be made by an experienced clinician based on the preponderance of available evidence for a given patient without adhering to a strict algorithm.

Staller K, Neshatian L, Lembo A, Bharucha AE. AGA Clinical Practice Update on Evaluation and Management of Refractory Constipation: Expert Review. 

Clinical Gastroenterology and Hepatology. 

American Gastroenterological Association. New expert guidance urges caution before surgery for patients with treatment-resistant constipation. January 7, 2026. Accessed January 8, 2026. 

https://www.eurekalert.org/news-releases/1111165

International Foundation for Gastrointestinal Disorders. Chronic Constipation. Accessed January 8, 2026. 

https://iffgd.org/gi-disorders/lower-gi-disorders/constipation/

Brenner D. Real-World Data Highlight a New Approach to Chronic Constipation, With Darren Brenner, MD. December 15, 2025. Accessed January 8, 2026. 

https://www.hcplive.com/view/real-world-data-highlight-a-new-approach-to-chronic-constipation-with-darren-brenner-md

Refractory constipation, affecting a subset of patients unresponsive to standard treatments, poses significant healthcare challenges. The American Gastroenterological Association has issued a clinical practice update with 14 best-practice advice statements to guide clinicians in diagnosing and managing this condition. Recommendations include excluding secondary causes, confirming slow colonic transit, and ensuring comprehensive trials of available therapies. Surgical options, such as colectomy, are considered for non-responders but carry risks. Psychological evaluation is advised pre-surgery, and contraindications include upper-gut dysmotility and untreated psychiatric conditions.

The document outlines 14 best-practice advice statements for diagnosing and managing refractory constipation, with an emphasis on surgical intervention. 

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

, poorer quality of life is linked to internalizing mental health problems, parental illness perceptions, multiple allergens, and a history of 

“The study highlights how parental perceptions are intertwined with the child’s emotions and behaviors, and in some cases, are associated with an impaired QoL,” wrote study investigator Laura Polloni, PsyD, from the Food Allergy Referral Center at Padua University Hospital in Italy, and colleagues.

Food allergy affects approximately 8% of children in the US, increasing to 11% when parent-reported cases not confirmed by specialists are included.

Prior research has demonstrated substantial discrepancies between medically diagnosed food allergy and caregiver reports.

Parental beliefs about a disease and its treatment can, in turn, shape how children manage their illness, influencing attitudes, emotions, behaviors, treatment adherence, health outcomes, and overall quality of life.

In this cross-sectional study, investigators examined the relationship between parental illness perception, mental health, and quality of life among children with food allergies. The sample included 79 parents (mean age, 42.94 years; 53% mothers) of children aged 3 – 12 years (mean age, 7.97 years; 56% male), recruited during outpatient visits at the Food Allergy Referral Centre of the Veneto Region in Padua (North-Eastern Italy) over 6 months. Most children had multiple food allergies (84%) and a history of anaphylaxis (86%).

Participants completed the Food Allergy Quality of Life Questionnaire—Parent Form (FAQLQ-PF), Strengths and Difficulties Questionnaire (SDQ), and Brief Illness Perception Questionnaire (B-IPQ). The SDQ assessed emotional and behavioral domains (hyperactivity and inattention, peer problems, and prosocial behavior), with higher scores indicating greater difficulties (except prosocial behavior).

B-IPQ evaluated cognitive and emotional illness representations across 9 dimensions: timeline (perceived duration of illness), identity (symptoms a person associates with the illness), personal control (the belief that the individual can control their illness), treatment control (the belief that the illness can be managed or cured through treatment), concern (worry of the illness), emotions (the emotional impact of the illness), coherence (the degree to which a person understands their illness), cause (personal ideas about the origins of the illness). A higher score indicated stronger illness perception.

FAQ-PF scores ranged from 2.98 to 3.18 (0 - 6 scale). The mean SDQ total score for emotional-behavioral difficulties was 10.99, within normal limits, with similar internalizing and externalizing profiles. Parents perceived timeline, identity, concern, emotions, and consequences for the child and parent as the dimensions of illness (B-IPQ) that had the greatest impact, while treatment control, coherence, and personal control had the least. Nearly half attributed (49%) the disease to genetics and not the environment, stress or chance, though no correlation with disease cause was observed (

Children’s quality of life was positively associated with behavioral difficulties (FAQLQ, 0.28), particularly internalizing problems (0.33). Quality of life was also positively associated with illness perceptions (B-IPQ, 0.64), including consequences for the child and parents (0.66), expected timeline (0.43), and emotional representation (0.63). Behavioral difficulties were negatively associated with parental control (SDQ, −0.27) and illness understanding (−0.24). Internalizing problems were negatively associated with parental control (−0.23) and positively associated with expected timeline (0.24).

A greater number of allergens was linked to worse quality of life (

 <.05), and prior anaphylaxis was associated with higher illness identity (

 <.05). Children aged 7 to 12 years reported lower personal and treatment control (

 =.006). The final model showed that internalizing problems, longer perceived timeline, and stronger emotional representation predicted poorer quality of life (

Additionally, multiple food allergies were moderately associated with a child’s worse quality of life (

 =.012) were associated with greater illness perception.

Male parenthood was associated with a lower perceived parental consequences (P =.023), emotional representation (

 =.010), but weakly associated with concern (

“The findings underscore the importance of understanding and exploring the illness perception of caregivers of pediatric patients with FA, as well as paying particular attention to the psychosocial–emotional aspects of the illness in both children and parents,” investigators wrote.

“Clinicians should investigate caregivers’ illness perceptions and offer evidence-based information, discussion of doubts and concerns, training in FA and anaphylaxis management, and, when appropriate, referral for psychological support.”

Polloni L, Ronconi L, Bonichini S, et al. Quality of Life, Mental Health, and Illness Perception in Pediatric Food Allergy. 

. 2025;12(12):1657. Published 2025 Dec 6. doi:10.3390/children12121657

Gupta RS, Warren CM, Smith BM, et al. The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States. 

Warren CM, Jiang J, Gupta RS. Epidemiology and Burden of Food Allergy. 

Teufel M, Biedermann T, Rapps N, et al. Psychological burden of food allergy. 

Gupta RS, Springston EE, Smith B, Pongracic J, Holl JL, Warrier MR. Parent report of physician diagnosis in pediatric food allergy. 

Children with food allergies often experience a diminished quality of life, influenced by internalizing mental health issues, parental illness perceptions, multiple allergens, and anaphylaxis history. Parental beliefs significantly impact children's management of their allergies, affecting their emotions, behaviors, and treatment adherence. A study involving 79 parents revealed that children's quality of life is closely linked to behavioral difficulties and illness perceptions. Factors such as the number of allergens, anaphylaxis history, and parental perceptions play crucial roles. Clinicians are encouraged to address caregivers' illness perceptions and provide comprehensive support.

A study links caregiver beliefs, mental health challenges, multiple allergens, and prior anaphylaxis to worse food allergy–related quality of life in pediatric patients.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Briquilimab therapy may lead to rapid and sustained disease control in patients with 

, new data suggest, with the majority of users achieving complete symptom resolution within weeks.

These data were announced by Jasper Therapeutics, Inc., highlighting the effects of patients with CSU given briquilimab, an investigational monoclonal antibody designed to target KIT (CD117). CSU itself is associated with various negative comorbidities and is known to impact approximately 1% of the general population around the world, including approximately 3 million people in the US.

“We are very pleased to present data from additional patients enrolled in the BEACON study, which reaffirms the potential of briquilimab to drive rapid and durable disease control in patients with CSU,”  Daniel Adelman, MD, the acting Chief Medical Officer of Jasper, said in a statement.

 “We are also pleased by the performance of the 180mg Q8W dose in the open label extension study, with the strong efficacy observed in CSU and CIndU patients.”

In their announcement, Jasper highlighted these encouraging updated clinical findings from the phase 1b/2a BEACON study in adults with CSU. They also released findings from an ongoing open-label extension involving patients with CSU and chronic inducible urticaria (CIndU). Briquilimab is being currently assessed for mast cell–mediated conditions such as asthma, CSU, and CIndU.

The BEACON analysis was designed as a randomized, double-blind, placebo-controlled phase 1b/2a trial evaluating escalating doses of briquilimab administered subcutaneously in adults with moderate-to-severe CSU. These patients had been symptomatic despite the use of high-dose antihistamine therapy.

In their main objectives, BEACON investigators focused on safety and tolerability. Secondary outcomes involved assessment of clinical activity and pharmacokinetic and pharmacodynamic impacts on patients with CSU. Clinical efficacy was mainly determined via the Urticaria Activity Score over 7 days (UAS7). This combines the Hives Severity Score and daily Itch Severity Score on a scale ranging from 0 - 42.

The updated dataset incorporates 8 newly involved participants in the 240 mg/180 mg every-8-weeks patient group, 2 of whom were placed into the placebo arm. The mean reduction, among patients given briquilimab (n=6), in UAS7 from the point of baseline reached 31.0 points at the 12-week mark. A rapid level of symptom resolution was noted by the BEACON investigators, with 83% of those treated attaining a complete response by Week 3.

At the 12-week mark, complete responses were shown to be maintained by 67% of briquilimab-treated study subjects. Additionally, across the BEACON study, briquilimab continued to demonstrate a strong safety profile. The investigative team highlighted a lack of any dose-limiting toxicities and the uncommon observation of adverse events associated with KIT inhibition. AEs did appear were generally mild in severity, and did not lead to treatment discontinuation or delays in use. Most of these AEs resolved with continued dosing.

In the open-label extension study of BEACON, individuals with CSU who completed BEACON and individuals with CIndU who completed follow-up in the SPOTLIGHT study, were included. All of those assessed were treated with briquilimab 180 mg every 8 weeks. Efficacy outcomes from 36 patients with CSU and 17 with CIndU were reported after they completed at least 12 weeks of follow-up.

By this 12-week mark, 58% of participants with CSU attained a complete response. 75% attained either complete response or well-controlled disease, the latter being defined as UAS7 scores of 6 or under. Among those in the CIndU cohort, 65% of individuals evaluated attained either a complete or partial response at the 16-week mark, corresponding to 8 weeks following the second dose.

“Taken together with the favorable safety and tolerability profile observed in both studies, we believe these data are sufficient to support a differentiated profile for briquilimab in chronic urticaria,” Adelman said in a statement.

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria. Jasper Therapeutics. January 8, 2025. 

https://www.globenewswire.com/news-release/2026/01/08/3215192/0/en/Jasper-Therapeutics-Reports-Positive-Updated-Data-from-Briquilimab-Studies-in-Chronic-Spontaneous-Urticaria.html

Kolkhir P, Bonnekoh H, Maurer M, et al. Chronic Spontaneous Urticaria: A Review. JAMA. 2024 Nov 5;332(17):1464-1477. 

Briquilimab, an investigational monoclonal antibody targeting KIT (CD117), shows promise in rapidly and sustainably controlling chronic spontaneous urticaria (CSU). In the BEACON study, briquilimab demonstrated significant efficacy, with 83% of patients achieving complete symptom resolution by Week 3 and 67% maintaining this response at 12 weeks. The therapy also exhibited a strong safety profile, with no dose-limiting toxicities. In an open-label extension, 58% of CSU patients achieved complete response by 12 weeks. These findings suggest briquilimab's potential as a differentiated treatment for chronic urticaria.

Jasper Therapeutics has released new, positive findings on the use of briquilimab, a novel antibody therapy targeting KIT (CD117), in patients with CSU.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

Mishaela Rubin, MD, MS, is a professor of medicine at Columbia University Irving Medical Center.

Videos

Rubin discusses an analysis of Ascendis’s program for patients who had received PTH treatment but weren’t eligible for clinical trials of palopegteriparatide.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Thyroid Disorders

Palopegteriparatide Allows for PTH Tapering in Hypoparathyroidism, With Mishaela Rubin, MD, MS

A trio of professional societies voice concerns about certain elements of the Dietary Guidelines for Americans, 2025–2030, and their potential negative health impacts.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

New Dietary Guidelines Draw Criticism For High Fat Dairy, Protein Recommendations

The FDA has not approved the sNDA for tasimelteon in jet lag disorder in its current form, citing positive efficacy but limited real-world applicability. 


FDA News

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

FDA Denies Tasimelteon’s Supplemental New Drug Application For Jet Lag Disorder

This video segment outlines the clinical features of familial chylomicronemia syndrome and introduces the emerging role of novel triglyceride-lowering therapies.

Video Series

 Understanding Updates in FCS Management with Newer Therapies

Clinically meaningful improvements in global IBS symptom severity were observed as early as week 1 and sustained through week 7.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

EBX-102-02 Shows Benefit for IBS-C and IBS-D in Phase 2a TrIuMPH Trial

This study evaluated the drug survival of different biologic therapies for patients with psoriasis in a routine clinical practice setting.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Ustekinumab Superior for Drug Survival to Other Psoriasis Biologics for Bio-Naïve

The Q4 recap for gastroenterology spotlights GI FDA news, new AGA guidelines, trial data for UC therapies, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Q4 2025 Recap: Gastroenterology News and Updates

Current Pathway Treatment Targets in GCA

Meta-analysis shows exercise may match therapy in improving depressive symptoms, with moderate-intensity and 13–36 sessions offering the greatest benefit.

Latest News

5 Pulmonology Headlines You Missed in December 2025

Depression's Implied Bilateral Link With Chronic Kidney Disease Progression

AGA Urges Caution Around Surgery for Refractory Constipation in Clinical Practice Update

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria